Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

References

• Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–440. doi:10.1080/0036552080260096119101844
   PubMed Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Høie O, et al. Clinical course in crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438. doi:10.1016/j.cgh.2007.09.00218054751
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B. Epidemiology and natural history task force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) hospitalizations and surgery in Crohn’s disease. Gut. 2012;61(4):622–629. doi:10.1136/gutjnl-2011-30139722267595
   PubMed Web of Science ®Google Scholar
• Magro F, Rodrigues A, Vieira AI, et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis. 2012;18:573–583. doi:10.1002/ibd.2181521793126
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761–769. doi:10.1016/S0016-5085(99)70332-X10500056
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476. doi:10.1056/NEJMoa05051616339095
   PubMed Web of Science ®Google Scholar
• Danese S, Angelucci E, Malesci A, Caprilli R. Biological agents for ulcerative colitis: hypes and hopes. Med Res Rev. 2008;28:201–218. doi:10.1002/(ISSN)1098-112817464967
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007;13:2328–2332. doi:10.3748/wjg.v13.i16.232817511032
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut. 2011;60:780–787. doi:10.1136/gut.2010.22112721209123
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265. doi:10.1053/j.gastro.2011.10.03222062358
   PubMed Web of Science ®Google Scholar
• Afif W, Leighton JA, Hanauer SB, et al. An open-label study of Adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15:1302–1307. doi:10.1002/ibd.2092419408340
   PubMed Web of Science ®Google Scholar
• Trinder MW, Lawrance IC. Efficacy of Adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol. 2009;24:1252–1257. doi:10.1111/jgh.2009.24.issue-719220669
   PubMed Web of Science ®Google Scholar
• García-Bosch O, Gisbert JP, Canas-Ventura A, et al. Observational study on the efficacy of Adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis. 2013;7:717–722. doi:10.1016/j.crohns.2012.10.00423142005
   PubMed Web of Science ®Google Scholar
• Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with Adalimumab or infliximab: long-term follow-up of a single-center cohort. Aliment Pharmacol Ther. 2010;32:522–528. doi:10.1111/j.1365-2036.2010.04380.x20500733
   PubMed Web of Science ®Google Scholar
• Taxonera C, Estelle J, Fernandez-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33:340–348. doi:10.1111/apt.2010.33.issue-321133961
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Biancone L, Daperno M, et al. P230 Adalimumab in active ulcerative colitis: a “real-life” observational study. J Crohns Colitis. 2012;6(Suppl 1):S101–S101. doi:10.1016/S1873-9946(12)60250-5
   Google Scholar
• Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and post-marketing surveillance. J Rheumatol Suppl. 2014;91:47–55. doi:10.3899/jrheum.14010224789000
   PubMedGoogle Scholar
• World Health Organization. Expert committee on biological standardization In: Guidelines on Evaluation of Similar Biotherapeutic Products. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed september 23, 2009.
   Google Scholar
• Adalimumab biosimilar; autoimmune disorders; rheumatoid arthritis; juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis. Exemptia; 2019 Available from: https://exemptia.com/zydus-launches-worlds-first-biosimilar-of-adalimumab Accessed 15, 2019.
   Google Scholar
• Bandyopadhyay S, Mahajan M, Mehta T, et al. Physicochemical and functional characterization of a biosimilar Adalimumab ZRC-3197. Biosimilars. 2015;5:1–18.
   Google Scholar
• Jani RH, Gupta R, Bhatia G, et al. A prospective, randomized, double-blind, multi-center, parallel-group, active controlled study to compare efficacy and safety of biosimilar Adalimumab (Exemptia; ZRC-3197) and Adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis. 2016;19:1157–1168. doi:10.1111/1756-185X.1271126176644
   PubMed Web of Science ®Google Scholar
• Midha V, Mahajan R, Mehta V, et al. Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate to severe ulcerative colitis. Intest Res. 2018;16:83–89. doi:10.5217/ir.2018.16.1.8329422802
   PubMed Web of Science ®Google Scholar
• Kamat N, Kedia S, Ghoshal UC, et al. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: a multicenter study. Indian J Gastroenterol. 2019;38(1):44–54. doi:10.1007/s12664-018-0922-130645725
   PubMed Web of Science ®Google Scholar
• Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guidelines for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144–164.30137275
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A–36A. doi:10.1155/2005/269076
   PubMed Web of Science ®Google Scholar
• Christensen KR, Steenholdt C, Brynskov J. Clinical outcome of Adalimumab therapy in patients with ulcerative colitis previously treated with Infliximab: a Danish single-center cohort study. Scand J Gastroenterol. 2015;50(8):1018–1024. doi:10.3109/00365521.2015.101955825861832
   PubMed Web of Science ®Google Scholar
• Szepes Z, Bálint A, Szücs M, et al. Short and medium-term efficacy of Adalimumab in ulcerative colitis – a multi center, prospective observational study. J Crohn’s Colitis. 2014;8(1):S208. doi:10.1016/S1873-9946(14)60464-5
   Google Scholar
• Bálint A, Farkas K, Palatka K, et al. Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice. J Crohns Colitis. 2016;10(1):26–30. doi:10.1093/ecco-jcc/jjv16926392413
   PubMed Web of Science ®Google Scholar
• Tursi A, Elisei W, Faggiani R, et al. Effectiveness and safety of Adalimumab to treat outpatient ulcerative colitis: a real-life multi-center, observational study in primary inflammatory bowel disease centers. Medicine (Baltimore). 2018;97(34):e11897. doi:10.1097/MD.000000000001189730142791
   PubMed Web of Science ®Google Scholar